Literature DB >> 21987154

Majocchi's granuloma.

Aline Lopes Bressan1, Roberto Souto da Silva, João Carlos Macedo Fonseca, Maria de Fátima G Scotelaro Alves.   

Abstract

We report the case of a man of 45 with superficial dermatophytosis longtime inadvertently treated with antibiotics and corticosteroids with subsequent progression to the deep form, known as granuloma Majocchi. Treatment with orally terbinafine was successful.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21987154     DOI: 10.1590/s0365-05962011000400030

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


  6 in total

Review 1.  Successful Treatment of Refractory Majocchi's Granuloma with Voriconazole and Review of Published Literature.

Authors:  H B Liu; F Liu; Q T Kong; Y N Shen; G X Lv; W D Liu; H Sang
Journal:  Mycopathologia       Date:  2015-06-05       Impact factor: 2.574

Review 2.  Trichophyton rubrum Infection Characterized by Majocchi's Granuloma and Deeper Dermatophytosis: Case Report and Review of Published Literature.

Authors:  Huilin Su; Li Li; Benlin Cheng; Junhao Zhu; Qiangqiang Zhang; Jinhua Xu; Min Zhu
Journal:  Mycopathologia       Date:  2016-12-21       Impact factor: 3.785

3.  Majocchi's granuloma - case report.

Authors:  Izabel Cristina Soligo Kanaan; Talita Batalha Pires dos Santos; Bernard Kawa Kac; Ariane Molinaro Vaz de Souza; Ana Maria Mosca de Cerqueira
Journal:  An Bras Dermatol       Date:  2015 Mar-Apr       Impact factor: 1.896

4.  Case for diagnosis.

Authors:  Alejandro Molina-Leyva; Santiago Perez-Parra; Federico Garcia-Garcia
Journal:  An Bras Dermatol       Date:  2014 Sep-Oct       Impact factor: 1.896

5.  The First Reported Case of Majocchi's Granuloma with Malbranchea sp. in an Immunocompetent Patient.

Authors:  Anusha Govind; Nathan L'Etoile; Gustavo Vasquez
Journal:  Case Rep Infect Dis       Date:  2017-08-30

Review 6.  Majocchi's granuloma: current perspectives.

Authors:  Hazal Boral; Murat Durdu; Macit Ilkit
Journal:  Infect Drug Resist       Date:  2018-05-22       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.